proxyvotesnow.com

Home › Companies › ROCKET PHARMACEUTICALS INC. › 2024-2025

ROCKET PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ROCKET PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 15Reported items
  • 219Asset managers
  • 2,405Fund votes
  • 2025-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ROCKET PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ROCKET PHARMACEUTICALS INC.

These tallies are ROCKET PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ROCKET PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-18
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Roderick Wong, M.D. 78,146,900---- 991,94812,227,613 Majority: yes
Elect Director: Elisabeth Björk, M.D., Ph.D. 76,976,311---- 2,162,53712,227,613 Majority: yes
Elect Director: Carsten Boess 78,224,283---- 914,56512,227,613 Majority: yes
Elect Director: Mikael Dolsten, M.D., Ph.D. 76,051,973---- 3,086,87512,227,613 Majority: yes
Elect Director: Pedro Granadillo 73,571,818---- 5,567,03012,227,613 Majority: yes
Elect Director: Gotham Makker, M.D. 73,798,301---- 5,340,54712,227,613 Majority: yes
Elect Director: Fady Malik, M.D., Ph.D. 78,249,290---- 889,55812,227,613 Majority: yes
Elect Director: Piratip Pratumsuwan 78,595,512---- 543,33612,227,613 Majority: yes
Elect Director: Gaurav Shah, M.D. 78,411,712---- 727,13612,227,613 Majority: yes
Elect Director: David P. Southwell 55,352,568---- 23,786,28012,227,613 Majority: yes

Source: ROCKET PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the ROCKET PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 219 asset managers that disclosed a ROCKET PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ROCKET PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-18.

Combines 7 wordings of this item as funds reported it.

99.5% fund support · no official result

FOR 99.2%

The 210 asset managers below cast 99.5% of the shares they voted on this item FOR (89,441,191 for, 360,146 against).

FOR: 89,441,191 (99.3%)AGAINST: 360,146 (0.4%)ABSTAIN: 201,916 (0.2%)NOT VOTED: 77,356 (0.1%)
Largest asset managers voting on “Consider and act upon a non-binding, advisory vote on the compensation of our named executive officers;” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP16,734,2170 00For
Vanguard11,219,885654 00For
Wellington7,225,9200 00For
BlackRock5,797,2360 00For
State Street5,264,7530 00For
MAVERICK CAPITAL LTD4,869,7250 00For
SUVRETTA CAPITAL MANAGEMENT, LLC4,094,3870 00For
WESTFIELD CAPITAL MANAGEMENT CO LP3,531,8880 00For
T. Rowe Price2,808,1930 00For
Federated Hermes2,762,6230 00For
Putnam2,031,5780 00For
GEODE CAPITAL MANAGEMENT, LLC2,007,2290 00For
Fidelity1,833,6340 00For
Charles Schwab1,376,2040 00For
HARBOR FUNDS1,232,8350 00For
PICTET ASSET MANAGEMENT SA1,191,5680 00For
MPM BioImpact LLC1,146,6600 00For
Novo Holdings A/S1,100,0000 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC1,049,2020 00For
COMERICA BANK823,9080 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Invesco669,7840 00For
Nantahala Capital Management, LLC629,7490 00For
Siren, L.L.C.591,2630 00For
Citadel500,0330 00For

Showing the 25 largest of 210 asset managers. See all 210 in the interactive database.

2. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD 30%
FOR: 55,352,568WITHHELD: 23,786,280

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David P. Southwell”): 55,352,568 for, 23,786,280 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 51.9% for, 22% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (17,043,543 for, 0 against).

FOR 64%ABSTAIN 36%
FOR: 17,043,543 (63.7%)ABSTAIN: 9,694,685 (36.3%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 6540For
BlackRock00 2,621,2980Abstain
State Street5,3340 1,915,5120Abstain
Fidelity1,785,1040 34,4620For
Federated Hermes1,363,5560 00For
HARBOR FUNDS00 1,232,8350Abstain
T. Rowe Price1,186,6720 00For
Putnam00 1,015,7890Abstain
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab00 686,4800Abstain
TIAA00 392,8350Abstain
Hartford343,2300 00For
Invesco00 322,4380Abstain
Equitable16,9560 194,8840Abstain
Goldman Sachs00 194,1020Abstain
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock118,4550 25,6610For
QUANTITATIVE MASTER SERIES LLC00 131,1340Abstain
Prudential/PGIM00 119,1880Abstain
Mercer Funds00 110,1610Abstain
Direxion Shares ETF Trust00 92,0250Abstain
Morgan Stanley00 76,4200Abstain
MassMutual59,2390 00For
Lincoln Financial00 58,7010Abstain

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

3. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,224,283WITHHELD: 914,565

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Carsten Boess”): 78,224,283 for, 914,565 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 73% for, 0.9% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (26,738,085 for, 0 against).

FOR 99.9%
FOR: 26,738,085 (100.0%)ABSTAIN: 143 (0.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

4. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,249,290WITHHELD: 889,558

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 78,249,290 for, 889,558 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 73% for, 0.9% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (26,738,228 for, 0 against).

FOR 99.9%
FOR: 26,738,228 (100.0%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

5. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gotham Makker, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 73,798,301WITHHELD: 5,340,547

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gotham Makker, M.D.”): 73,798,301 for, 5,340,547 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 69% for, 5% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (24,510,325 for, 0 against).

FOR 92%8%
FOR: 24,510,325 (91.7%)ABSTAIN: 2,227,903 (8.3%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 6540For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes00 1,363,5560Abstain
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab00 686,4800Abstain
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X00 149,6260Abstain
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

6. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

99.0% Majority: yes · of votes cast

FOR 99.0%
FOR: 78,411,712WITHHELD: 727,136

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 78,411,712 for, 727,136 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 73% for, 0.7% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (26,738,228 for, 0 against).

FOR 99.9%
FOR: 26,738,228 (100.0%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

7. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 76,051,973WITHHELD: 3,086,875

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 76,051,973 for, 3,086,875 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 71% for, 3% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (24,358,883 for, 0 against).

FOR 91%9%
FOR: 24,358,883 (91.1%)ABSTAIN: 2,379,345 (8.9%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes00 1,363,5560Abstain
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam00 1,015,7890Abstain
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

8. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Pedro Granadillo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%
FOR: 73,571,818WITHHELD: 5,567,030

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Pedro Granadillo”): 73,571,818 for, 5,567,030 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 69% for, 5% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (25,875,339 for, 0 against).

FOR 97%
FOR: 25,875,339 (96.8%)ABSTAIN: 862,889 (3.2%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 6540For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA00 392,8350Abstain
Hartford343,2300 00For
Invesco322,4380 00For
Equitable138,0800 73,7600For
Goldman Sachs123,5000 70,6020For
Harbor Funds II182,4820 00For
Global X00 149,6260Abstain
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM8,0700 111,1180Abstain
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

9. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Piratip Pratumsuwan

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 78,595,512WITHHELD: 543,336

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Piratip Pratumsuwan”): 78,595,512 for, 543,336 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 74% for, 0.6% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (26,738,228 for, 0 against).

FOR 99.9%
FOR: 26,738,228 (100.0%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

10. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 78,146,900WITHHELD: 991,948

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 78,146,900 for, 991,948 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 73% for, 1.0% withheld (74% of the company cast a for/withheld vote).

The 63 asset managers below cast 100% of the shares they voted on this item FOR (26,710,384 for, 0 against).

FOR 99.8%
FOR: 26,710,384 (99.9%)ABSTAIN: 27,844 (0.1%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,905,5470 6540For
BlackRock2,621,2980 00For
State Street1,920,8100 360For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

11. Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025;

AUDIT-RELATED

Meeting held 2025-06-18.

Combines 2 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 63 asset managers below cast 99.9% of the shares they voted on this item FOR (26,738,118 for, 110 against).

FOR: 26,738,118 (100.0%)AGAINST: 110 (0.0%)ABSTAIN: 0 (0.0%)
Largest asset managers voting on “Ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting f” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,736110 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam1,015,7890 00For
MUTUAL FUND SERIES TRUST770,6910 00For
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For

Showing the 25 largest of 63 asset managers. See all 63 in the interactive database.

12. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Elisabeth Bjork, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-06-18.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 76,976,311WITHHELD: 2,162,537

ROCKET PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elisabeth Björk, M.D., Ph.D.”): 76,976,311 for, 2,162,537 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 106,753,886 outstanding shares: 72% for, 2% withheld (74% of the company cast a for/withheld vote).

The 59 asset managers below cast 100% of the shares they voted on this item FOR (24,927,391 for, 0 against).

FOR 96%
FOR: 24,927,391 (96.0%)ABSTAIN: 1,035,146 (4.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard10,906,2010 00For
BlackRock2,621,2980 00For
State Street1,920,8460 00For
Fidelity1,819,5660 00For
Federated Hermes1,363,5560 00For
HARBOR FUNDS1,232,8350 00For
T. Rowe Price1,186,6720 00For
Putnam00 1,015,7890Abstain
Charles Schwab686,4800 00For
TIAA392,8350 00For
Hartford343,2300 00For
Invesco322,4380 00For
Equitable211,8400 00For
Goldman Sachs194,1020 00For
Harbor Funds II182,4820 00For
Global X149,6260 00For
John Hancock144,1160 00For
QUANTITATIVE MASTER SERIES LLC131,1340 00For
Prudential/PGIM119,1880 00For
Mercer Funds110,1610 00For
Direxion Shares ETF Trust92,0250 00For
Morgan Stanley76,4200 00For
MassMutual59,2390 00For
Lincoln Financial58,7010 00For
Delaware/Macquarie58,0000 00For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

13. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2025-06-18.

64% fund support · no official result

FOR 64%AGAINST 36%

The 4 asset managers below cast 64% of the shares they voted on this item FOR (592,770 for, 336,956 against).

FOR: 592,770 (63.8%)AGAINST: 336,956 (36.2%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
JPMorgan485,5230 00For
NORDEA INVESTMENT MANAGEMENT AB0263,746 00Against
EFG Asset Management (North America) Corp.107,2470 00For
Desjardins Global Asset Management Inc.073,210 00Against

14. Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.

SECTION 14A SAY-ON-PAY VOTES

Meeting held 2024-06-13 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

0% fund support · no official result

AGAINST 100%

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 78 against).

AGAINST: 78 (100.0%)
Largest asset managers voting on “Approval of the compensation of the Company's named executive officers, on a non-binding, advisory basis.” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
COLDSTREAM CAPITAL MANAGEMENT INC078 00Against
Echo45 Advisors LLC00 00--

15. Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockholders in 2026, or until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Elisabeth Bj?rk, M.D., Ph.D.

DIRECTOR ELECTIONS

Meeting held 2025-06-18.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (5,000 for, 0 against).

FOR: 5,000 (100.0%)
Largest asset managers voting on “Election of the ten directors named in the proxy statement to hold office until the annual meeting of stockhol” at ROCKET PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
SA FUNDS INVESTMENT TRUST3,5760 00For
Humankind Benefit Corp1,4240 00For

Largest ROCKET PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of ROCKET PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 106,753,886 shares outstanding at the time of that meeting.

Top ROCKET PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 15.68%
2Vanguard 10.51%
3Wellington 6.77%
4BlackRock 5.43%
5State Street 4.93%
6MAVERICK CAPITAL LTD 4.56%
7SUVRETTA CAPITAL MANAGEMENT, LLC 3.84%
8WESTFIELD CAPITAL MANAGEMENT CO LP 3.31%
9T. Rowe Price 2.63%
10Federated Hermes 2.59%

Reported ROCKET PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ROCKET PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
RTW Investments, LP 17.04% DEF14A
Wellington Management 11.83% 13F
BlackRock 6.81% 13F
Vanguard Group 6.20% 13F
Maverick Capital, Ltd. 5.20% DEF14A
State Street 3.47% 13F
Gaurav Shah, M.D. 3.01% DEF14A
T. Rowe Price 2.85% 13F
Morgan Stanley 2.47% 13F
Geode Capital 1.87% 13F

Percentages above are of 106,753,886 shares outstanding, as reported by ROCKET PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ROCKET PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ROCKET PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-18, in the 2024-2025 proxy season, 219 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,405 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ROCKET PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Consider and act upon a non-binding, advisory vote on the compensation of our named executive… — the reporting funds cast 99.5% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ROCKET PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.